Phase 1 Vasculitis Trial, Recruiting NCT06308978 Sponsor: Fate Therapeutics Condition: Vasculitis
Back to Vasculitis

Phase 1 Vasculitis Trial, Recruiting

NCT06308978
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 12 and 70 years old.
  • You have been diagnosed with an active B-cell related autoimmune disease, specifically lupus (SLE), a type of blood vessel inflammation (AAV), inflammatory muscle disease (IIM), or systemic sclerosis (SSc), confirmed by standard medical tests.
  • Your disease is moderate to severe, and at least two previous treatments have not worked well enough for you.
  • Your heart, lungs, liver, kidneys, and other organs are working well enough to handle the treatment.
  • You are able to give your agreement to take part (or, if under 18, a parent or guardian can give consent on your behalf) and are able to follow the study's requirements.

Who may not be able to join:

  • Women who are currently pregnant or breastfeeding.
  • People who have significant problems with their heart, lungs, liver, or kidneys.
  • People who have had a serious infection recently or currently have one.
  • People who have or recently had cancer, have previously received a type of cell therapy called CAR T-cell therapy, or have had an organ transplant.
  • People who have a known allergy to any of the treatments used in this study.
  • People who weigh less than 50 kg (110 lbs).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 858-875-1800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Fate Therapeutics
Registry
ClinicalTrials.gov
Start date
28 March 2024
Est. completion
30 September 2027

Where this trial is recruiting

🇫🇷 France 🇸🇪 Sweden 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Number of participants with treatment-emergent adverse events (TEAEs); Number of participants with serious TEAEs; Number of participants with dose-limiting toxicities (DLTs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov